Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) inhibitors, are also gaining traction for their potential to enhance the immune system’s response against cancer [16]. Here, PDCD1 is linked to cancer.